PIK3CG and breast cancer: Furthermore, studies have demonstrated that the IGF1R/p110β/AKT/mTOR axis confers resistance to BYL-719 in PIK3CA mutant breast cancers.136 Similarly, a study showed that targeting PI3K/Akt signaling pathway components can be used to overcome drug resistance in cancer therapy.137